Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

Antonio Russo; Marta Castiglia; Alessandro Perez; Francesco Passiglia; Angela Listi'; Chiara Ancona; Emmanuela Musso; Sergio Rizzo

Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

Antonio Russo, Marta Castiglia, Alessandro Perez, Francesco Passiglia, Angela Listi', Chiara Ancona, Emmanuela Musso, Sergio Rizzo

Risultato della ricerca: Other

Abstract

Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients

Lingua originale	English
Numero di pagine	0
Stato di pubblicazione	Published - 2017

Accesso al documento

OA Link

Fingerprint Entra nei temi di ricerca di 'Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab'. Insieme formano una fingerprint unica.

Cita questo

Russo, A., Castiglia, M., Perez, A., Passiglia, F., Listi', A., Ancona, C., Musso, E., & Rizzo, S. (2017). Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab.

@conference{5e77de80376841368cf989fd526cc7c7,

title = "Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab",

abstract = "Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients",

author = "Antonio Russo and Marta Castiglia and Alessandro Perez and Francesco Passiglia and Angela Listi' and Chiara Ancona and Emmanuela Musso and Sergio Rizzo",

year = "2017",

language = "English",

}

TY - CONF

T1 - Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

AU - Russo, Antonio

AU - Castiglia, Marta

AU - Perez, Alessandro

AU - Passiglia, Francesco

AU - Listi', Angela

AU - Ancona, Chiara

AU - Musso, Emmanuela

AU - Rizzo, Sergio

PY - 2017

Y1 - 2017

N2 - Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients

AB - Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients

UR - http://hdl.handle.net/10447/245238

M3 - Other

ER -